PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL
S Stefani, MG Saggia, EA SantosVolume:
10
Year:
2007
Language:
english
DOI:
10.1016/s1098-3015(10)65190-x
File:
PDF, 74 KB
english, 2007